Home Cart Sign in  
Chemical Structure| 1477949-42-0 Chemical Structure| 1477949-42-0

Structure of Santacruzamate A
CAS No.: 1477949-42-0

Chemical Structure| 1477949-42-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Santacruzamate A (CAY-10683, STA) is an effective selective HDAC2 inhibitor with an IC50 of 119 pM. STA also exhibits neuroprotective effects against β-amyloid fragment 25-35. It can be used in cancer and neurological disease research.

Synonyms: CAY-10683

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Santacruzamate A

CAS No. :1477949-42-0
Formula : C15H22N2O3
M.W : 278.35
SMILES Code : O=C(OCC)NCCCC(NCCC1=CC=CC=C1)=O
Synonyms :
CAY-10683
MDL No. :N/A
InChI Key :HTOYBIILVCHURC-UHFFFAOYSA-N
Pubchem ID :72946782

Safety of Santacruzamate A

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Santacruzamate A

epigenetics

Isoform Comparison

Biological Activity

Target
  • HDAC2

    HDAC2, IC50:119 pM

In Vitro:

Cell Line
Concentration Treated Time Description References
SW620 cells 10 µM 24 hours HDAC2 knockout upregulated NLRP3 expression, promoting GSDMD-dependent pyroptosis. PMC11131357
LS174T cells 10 µM 24 hours HDAC2 knockout upregulated NLRP3 expression, promoting GSDMD-dependent pyroptosis. PMC11131357
BV2 cells 10 μM 24 hours To investigate the inhibitory effect of SCA on LPS-induced inflammatory response, the results showed that SCA significantly reduced the release of IL-1β, IL-6, and TNF-α. PMC11019733
PC12 cells 10 μM 24 hours To investigate the effect of SCA on the function of excitatory synaptic receptors in neuronal cells, the results showed that SCA significantly reduced the protein expression of GluN2A, GluN2B, GluA1, and GluA2. PMC11019733
K562-R cells 0, 0.1, 0.25, 0.5 μM 48 hours The combined treatment of CAY10683 and IM significantly increased the apoptotic rate of K562-R cells, showing a synergistic effect. PMC9048251
LAMA84-R cells 0, 0.1, 0.25, 0.5 μM 48 hours The combined treatment of CAY10683 and IM significantly increased the apoptotic rate of LAMA84-R cells, showing a synergistic effect. PMC9048251
MDA-MB-231 25 μM 5 days Santacruzamate A inhibited the nuclear translocation of PD-L1, thereby reducing the production of NCS-induced pro-inflammatory cytokines. PMC11811057
HuT-78 cutaneous T-cell lymphoma cells 1.4 µM 72 hours To test the cytotoxicity of Santacruzamate A on HuT-78 cells, the results showed a GI50 value of 1.4 μM. PMC3879121
Human dermal fibroblast cells (hDF) >100 µM 72 hours To test the cytotoxicity of Santacruzamate A on human dermal fibroblast cells, the results showed a GI50 value greater than 100 μM. PMC3879121
MCF-7 23.7 μM 72 hours Inhibited cell proliferation PMC5065774
MCF-7 13.8 μM 72 hours Inhibited cell proliferation PMC5065774
HCT116 17.2 μM 72 hours Inhibited cell proliferation PMC5065774
HuT-78 36.0 μM 72 hours Inhibited cell proliferation PMC5065774
Molt-4 7.8 μM 72 hours Inhibited cell proliferation PMC5065774
HCT-116 colon cancer cells 29.4 µM 96 hours To test the cytotoxicity of Santacruzamate A on HCT-116 cells, the results showed a GI50 value of 29.4 μM. PMC3879121

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c-Nude mice Colorectal cancer xenograft model Intraperitoneal injection 5 mg/kg Daily for 12 days SCA combined with 5-FU or regorafenib significantly inhibited tumor growth and activated NLRP3-mediated pyroptosis. PMC11131357
C57BL/6J mice Complete Freund’s adjuvant (CFA)-induced chronic inflammatory pain model Intragastric administration 2, 10, 50 mg/kg Once daily for 3 days To investigate the effect of SCA on CFA-induced chronic inflammatory pain and related anxiety and depressive-like behaviors, the results showed that SCA significantly alleviated pain, anxiety, and depressive-like behaviors, and inhibited microglial activation in the ACC region. PMC11019733
NOD/SCID mice K562-R xenograft model intraperitoneal injection 50 mg/kg once daily for 21 days The combined treatment of CAY10683 and IM significantly suppressed the proliferation of K562-R cells in vivo, showing a synergistic effect. PMC9048251

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.59mL

0.72mL

0.36mL

17.96mL

3.59mL

1.80mL

35.93mL

7.19mL

3.59mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories